Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by M. Firoozrai
Total Records ( 2 ) for M. Firoozrai
  F. Ghazi , M. Firoozrai , B. Dabirmanesh and A. Shabani
  Angiotensin-Converting Enzyme (ACE) is a dipeptidyl carboxypeptidase (EC: 3.4.15.1) that catalyzes the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. Angiotesin II is responsible for an increase in blood pressure and maintenance of hypertension through the stimulation of oxidative stress. The relationship between Coronary Artery Disease (CAD), Angiotensin-Converting Enzyme (ACE) activity, ascorbic acid and serum antioxidant status in patients with coronary artery disease. A group of 65 patients with angiographically defined Coronary Artery Disease (CAD) and 60 normal control subjects were examined. The activity of Angiotensin-Converting Enzyme (ACE) was determined by the reversed-phase High Performance Liquid Chromatography (HPLC) to separate and quantify Hippuryl-Histidyl-Leucin (HHL) and Hippuric Acid (HA). Ferric Reducing Ability of Plasma (FRAP Assay) as a measure of antioxidant power was used. Serum ascorbic acid concentration was determined photometrically. The results demonstrated significant differences in ACE activity, antioxidant and ascorbic acid between CAD cases and normal controls. Increased levels of ACE activity in serum have been related to coronary artery disease. Serum ascorbic acid concentration (25.6±3.8 mg dL-1) and total antioxidant capacity (475.5±18.51 μM L-1) were significantly (p<0.05) decreased in CAD patients compared with controls.
  R. Shahsavari , A. Ehsani-Zonouz , M. Houshmand , A. Salehnia , G. Ahangari and M. Firoozrai
  This study was to evaluate the effect of the wild SKEO on activities and genes expression of hepatic Glycogen Phosphorylase (GP) and phosphoenolpyruvate carboxykinase (PEPCK) in normal and diabetic rats. The wild SKEO was orally administered at different doses (50 and 100 mg/kg/day) to normal as well as diabetic rats for 21 days. The levels of mRNA were determined using the quantitative real-time RT-PCR technique. The plasma glucose concentrations of diabetic rats receiving SKEO (100 mg kg-1) compared with diabetic control were significantly decreased. Hepatic GP activity and its mRNA levels of diabetic rats treated with SKEO moderately increased. The activity of hepatic PEPCK and its mRNA levels were significantly decreased in normal rats treated with SKEO (100 mg kg-1). The enhancement of PEPCK activity and its mRNA levels of diabetic treated rats with SEKO (100 mg kg-1) was significantly decreased compared with diabetic control. In conclusion, an excessive inhibition of PEPCK in liver of diabetic rats treated with the wild SKEO may contribute to the plasma glucose lowering action of SKEO that seems to be in relation with antioxidant properties of SKEO.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility